A new cancer drug, Opdivo, is working so well that pharmaceutical giant Bristol-Myers Squibb announced Monday it is stopping a trial in lung cancer two years ahead of schedule. Pasi Janne, professor of medicine at Dana-Farber Cancer Institute, is quoted.
Trending News
Search for Babesiosis Treatment Gets a New Map
New clues to help fight tick-borne disease
Can an AI ‘Co-Scientist’ Accelerate Cancer Research?
Nearly $7 million funds agentic AI tools to assist investigations into cancer’s most pressing…
First Large-Scale Study Shows How Doctors Use AI in Medicine
Which practitioners use artificial intelligence in the clinic, and what do they ask?